Department of Neurology, Paracelsus Medical University, Salzburg, Austria.
Division of Neuroradiology, Department of Radiology, Paracelsus Medical University Salzburg, Salzburg, Austria.
J Neurointerv Surg. 2018 Sep;10(9):869-873. doi: 10.1136/neurintsurg-2017-013583. Epub 2018 Jan 11.
To report the results of a retrospective analysis of prospectively collected data evaluating the safety and efficacy of a double layer stent engineered for carotid artery occlusive disease.
Between January 2014 and February 2017, 138 patients (25.4% women; median age 71 years) underwent Casper stent implantation for carotid artery stenosis. Eligibility criteria included stenosis >70% of vessel diameter (or >50% diameter with ulceration) in symptomatic patients or asymptomatic patients with >80% stenosis at the carotid bifurcation or in the proximal internal carotid artery. For all procedures, a distal embolic protection device was used. The primary endpoint was the rate of 90 day major adverse neurological events, defined as minor stroke, major stroke, or death by independent neurological assessment.
Stent deployment was completed successfully in all cases without documented technical failure. There were no adverse neurological events or mortalities within 90 days. One thromboembolic occlusion of a small distal branch of the anterior cerebral artery occurred during the procedure and resolved with systemic recombinant tissue plasminogen activator administration. New ischemic lesions, all clinically silent, were seen in 6.5% of patients on post-procedure cerebral MRI.
The Casper carotid stent demonstrated safety and efficacy in the treatment of carotid stenosis, with no technical failures and no adverse neurological events seen throughout the 90 day follow-up period. Its double layer structure seems to combine adequate plaque scaffolding with high vessel adaptability.
报告前瞻性收集的数据对颈动脉闭塞性疾病双层支架安全性和有效性评估的回顾性分析结果。
2014 年 1 月至 2017 年 2 月,138 例患者(25.4%为女性;中位年龄 71 岁)接受 Casper 支架置入术治疗颈动脉狭窄。入选标准包括症状性患者血管狭窄>70%(或溃疡处>50%直径狭窄),或无症状患者颈动脉分叉处或颈内动脉近端狭窄>80%。所有患者均使用远端血栓保护装置。主要终点为 90 天内主要不良神经事件(由独立神经评估定义为轻度卒中、重度卒中或死亡)发生率。
所有病例均成功完成支架置入,无技术失败。90 天内无不良神经事件或死亡。术中发生 1 例大脑前动脉小远端分支血栓栓塞闭塞,全身应用重组组织型纤溶酶原激活剂后得到解决。术后 6.5%的患者在脑 MRI 上发现新的缺血性病变,均为临床无症状。
在颈动脉狭窄的治疗中,Casper 颈动脉支架表现出安全性和有效性,90 天随访期间无技术失败和不良神经事件发生。其双层结构似乎结合了充分的斑块支撑和高血管适应性。